March 15, 2023

By Lynda Kiernan-Stone, Global AgInvesting Media

Biotech startup Tiamat Sciences explained that it is reinventing recombinant proteins by using the power of plants to provide animal-free growth factors with a reduced carbon footprint at a fraction of the cost.

Consequently, the startup announced that it has secured $2 million in seed-extension funding led by 8090 Industries. Also participating in this round, which brings total funding for the startup to-date to $5.4 million, were True ventures, Social Impact Capital, Cantos, Portfolia, Alexandria, Siddhi Capital, Sara Murray, Seed Folio, Sustainable Food Ventures, and Exponential Impact.

As an investment firm with an intention to lead the next industrial revolutions, 8090 Industries’ flagship Decarbonization Initiative focuses on transforming the industrial complex through breakthrough, zero-carbon technologies with significant economic advantages. 

New to the portfolio, and led by experienced biochemist and company CEO France-Emmanuelle Adil, Tiamat is on a mission to remove animals from science, and to be a driver of this next wave of biotechnology advances.

Using transient expression, vertical farming, and taking a data-driven approach, Tiamat’s platform produces a diverse offering of animal-free biomolecules that are highly active, and endotoxin- and pathogen-free. 

“Tiamat’s most versatile platform gives the flexibility the nascent markets need to validate and succeed in each stage of development,” said France-Emmanuelle Adil, founder and CEO, Tiamat Sciences.

This new financing comes just as the company is preparing for rapid growth, having recently seen a string of successes including additions of new products to its portfolio, a new patent, an increase of 1000x in yields in only six months, expansions into new markets, and the formation of new partnerships. 

“At 8090 Industries, we help build breakthroughs into category defining industrial juggernauts focused on decarbonizing every sector, which is why we’re incredibly excited to back France and her team at Tiamat – as they pioneer industrial-scale production of growth factors with their proprietary animal-free recombinant proteins that are 10x cheaper than the market today with plans to drive down costs by 1,000x in a few years,” said Rayyan Islam, co-founder and general partner, 8090 Industries. 

“With several engagements with leading protein companies already underway while its technology shows further promise for regenerative medicine and pharma, Tiamat is off to a fast start and industry leaders have taken serious notice.” 

On the heels of this growth and success, and with new funding in-hand, Tiamat is advancing toward new products and markets, and is preparing for commercialization beginning in March 2023 across the biotech, cellular agriculture, and regenerative medicine industries. 

The company anticipates its next round of funding to occur this year, which will support site expansions in North Carolina and Belgium ahead of schedule.

~ Lynda Kiernan-Stone is editor in chief with GAI Media, and is managing editor and daily contributor for Global AgInvesting’s AgInvesting Weekly News and  Agtech Intel News, as well as HighQuest Group’s Unconventional Ag. She can be reached at lkiernan-stone@globalaginvesting.com.

*The content put forth by Global AgInvesting News and its parent company HighQuest Partners is intended to be used and must be used for informational purposes only. All information or other material herein is not to be construed as legal, tax, investment, financial, or other advice. Global AgInvesting and HighQuest Partners are not a fiduciary in any manner, and the reader assumes the sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this site.